DRTSW Company Profile and Key Details

Alpha Tau Medical Ltd. earnings surprise history is a mixed track record. The quarter that ended May 18, 2026, missed forecasts by 110.42%. The prior quarter beat by 15.69%. Over the last six quarters, Apple has recorded several small beats. These include -2.06% in May 19, 2025.

DRTSW has shown weak momentum, losing -10.0% over the past week and -10.03% over the past quarter, though year-to-date performance is down -10.03%. Average 10-day trading volume of 124.34 thousand shares is significantly above the 3-month average of 67.16 thousand, indicating heightened recent market interest.

Alpha Tau Medical Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.03. This means the shares are trading above this model’s fair value.

Alpha Tau Medical Ltd. (NASDAQ:DRTSW) closed at $2.10 USD, losing -$0.19 (-8.30%) from the previous close of $2.29. The stock is currently mid-range between its 52-week high and low $0.33 and $2.29. With a market capitalization of about $982.75 million, Alpha Tau Medical Ltd. is classified as a small-cap and shows market-like volatility (beta ~1.20). Key stats such as the average daily volume over the past year has been around 34.12 thousand shares, trading with heavier-than-usual volume. Headquartered in Jerusalem, None, Alpha Tau Medical Ltd. operates in the Healthcare sector and the Medical - Specialties industry. Led by CEO Uzi Sofer, the company employs approximately 117 people and listed since March 06, 2026. Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer.

Alpha Tau Medical Ltd. (NASDAQ:DRTSW) shares are down -10.03% year-to-date Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Alpha Tau Medical Ltd. trading at a premium to the broader market with a P/E of -16.24.

Our AI price prediction model suggests that Alpha Tau Medical Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -88.1%, with price expected at $0.25 by November 24, 2023, within a range of $0.23 to $0.27

Alpha Tau Medical Ltd. trades at a P/E ratio of -16.24, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 14.07 reflecting a rich premium to book value. The P/FCF stands at -30.0, also below market averages. Compared to sector medians, Alpha Tau Medical Ltd. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.